Orasis Pharmaceuticals – Weekly Recap

Orasis Pharmaceuticals is a privately held ophthalmic company focused on developing and commercializing therapies for presbyopia, the age‑related loss of near vision. This weekly summary highlights the company’s recent emphasis on category education and prescriber engagement around its presbyopia eye‑drop treatment.

During Presbyopia Awareness Month, Orasis used its digital channels to spotlight eye‑care prescriber Dámaris Raymondi, O.D., FAAO, who discussed what she described as an “exciting new category” of presbyopia eye drops. The company directed audiences to important safety information and educational resources outlining the benefits and risks of this treatment option.

Through this campaign, Orasis reiterated its mission to “reshape near vision possibilities” for U.S. patients by promoting what it positions as a flexible treatment approach for presbyopia. The focus on real‑world prescriber perspectives indicates a strategy centered on building clinical credibility rather than relying solely on direct promotional messaging.

From a business standpoint, the heightened awareness efforts suggest ongoing commercial execution aimed at expanding adoption within the large U.S. presbyopia population. By engaging eye‑care professionals and emphasizing category education, Orasis is working to strengthen brand positioning in the emerging presbyopia eye‑drop segment and support sustained prescription growth over time.

If successful, this approach could enhance the company’s competitive profile in vision‑care therapeutics and reinforce its role in shaping standards of care for presbyopia management. Overall, the week underscored Orasis Pharmaceuticals’ continued focus on awareness, education, and prescriber partnerships to advance its presbyopia eye‑drop franchise.